相关实验视频

Updated: Jun 11, 2025

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

对于阿尔茨海默病的血液生物标志物的实际实施存在挑战

Michael Schöll¹, Inge M W Verberk², Marta Del Campo³

¹Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Mölndal, Sweden; Department of Psychiatry and Neurochemistry, University of Gothenburg, Mölndal, Sweden; Dementia Research Centre, Queen Square Institute of Neurology, University College London, London, UK; Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden.

The lancet. Healthy longevity

|October 6, 2024

概括

血液生物标志物为阿尔茨海默病 (AD) 诊断提供了一种有希望的,可访问的方法. 标准化对于克服各种临床环境中的挑战,以准确检测和治疗AD至关重要.

科学领域:

神经学神经学
生物标志物研究生物标志物研究
诊断医学诊断医学诊断医学

背景情况:

血液生物标志物正在成为阿尔茨海默病 (AD) 诊断的具有成本效益的工具.
从大脑脊髓液过渡到血液生物标志物用于粉样β病理需要仔细考虑.
广泛采用需要严格的标准化,以应对实施挑战.

研究的目的:

突出在各种临床环境中实施血液生物标志物用于AD诊断的挑战.
讨论分析前,分析前,混因素和并发症对血液生物标志物可靠性的影响.
探索记忆诊所和初级保健机构的具体实施障碍.

主要方法:

对阿尔茨海默病的血液生物标志物实施的当前研究的审查和综合.
分析与标准化,预分析/分析条件以及混因素相关的挑战.
检查在记忆诊所,初级保健和人口查中的不同实施场景.

主要成果:

血液生物标志物测量是强大的,但标准化是广泛采用的关键.
分析前/分析条件,混因素和并发症带来了重大挑战.
记忆诊所需要经验证的诊断准确性;初级保健需要教育和明确的指导方针.

结论:

血液生物标志物具有巨大的潜力,可以提高AD诊断的准确性和简化转诊.
通过标准化和定制战略解决实施挑战至关重要.
跨不同环境的整合将促进阿尔茨海默病的精准医学.

更多相关视频

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

Absolute Quantification of Aβ1-42 in CSF Using a Mass Spectrometric Reference Measurement Procedure

Absolute Quantification of Aβ_1-42 in CSF Using a Mass Spectrometric Reference Measurement Procedure

Published on: March 21, 2017

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...